Restasis Buyers Win Cert. Battle In Allergan Monopoly Case

Law360 (May 6, 2020, 4:52 PM EDT) -- Health care plans, welfare funds and other buyers of Allergan's extremely successful dry eye treatment Restasis have won class certification in the sweeping litigation accusing the drugmaker of illegally keeping generic rivals on the sidelines, with three firms tapped to head up their legal team.

In a lengthy decision out of New York federal court Tuesday, U.S. District Judge Nina Gershon certified a class of end-payors — which is estimated to cover up to 40,000 benefit plans as well as more than 1 million insured and uninsured consumers — over objections from Allergan that the group included too many uninjured buyers....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!